We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Boston Scientific (BSX) Stock Moves -0.03%: What You Should Know
Read MoreHide Full Article
The latest trading session saw Boston Scientific (BSX - Free Report) ending at $90.43, denoting a -0.03% adjustment from its last day's close. The stock outperformed the S&P 500, which registered a daily loss of 0.39%. On the other hand, the Dow registered a loss of 0.61%, and the technology-centric Nasdaq decreased by 0.32%.
Prior to today's trading, shares of the medical device manufacturer had gained 0.01% over the past month. This has outpaced the Medical sector's loss of 0.78% and lagged the S&P 500's gain of 3.6% in that time.
The investment community will be paying close attention to the earnings performance of Boston Scientific in its upcoming release. The company is forecasted to report an EPS of $0.65, showcasing a 18.18% upward movement from the corresponding quarter of the prior year. Simultaneously, our latest consensus estimate expects the revenue to be $4.39 billion, showing a 17.85% escalation compared to the year-ago quarter.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $2.46 per share and revenue of $16.58 billion, indicating changes of +20% and +16.4%, respectively, compared to the previous year.
Investors should also note any recent changes to analyst estimates for Boston Scientific. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, there's been no change in the Zacks Consensus EPS estimate. As of now, Boston Scientific holds a Zacks Rank of #3 (Hold).
Investors should also note Boston Scientific's current valuation metrics, including its Forward P/E ratio of 36.77. Its industry sports an average Forward P/E of 24.61, so one might conclude that Boston Scientific is trading at a premium comparatively.
We can also see that BSX currently has a PEG ratio of 2.66. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Medical - Products industry had an average PEG ratio of 2.31 as trading concluded yesterday.
The Medical - Products industry is part of the Medical sector. This group has a Zacks Industry Rank of 85, putting it in the top 34% of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Boston Scientific (BSX) Stock Moves -0.03%: What You Should Know
The latest trading session saw Boston Scientific (BSX - Free Report) ending at $90.43, denoting a -0.03% adjustment from its last day's close. The stock outperformed the S&P 500, which registered a daily loss of 0.39%. On the other hand, the Dow registered a loss of 0.61%, and the technology-centric Nasdaq decreased by 0.32%.
Prior to today's trading, shares of the medical device manufacturer had gained 0.01% over the past month. This has outpaced the Medical sector's loss of 0.78% and lagged the S&P 500's gain of 3.6% in that time.
The investment community will be paying close attention to the earnings performance of Boston Scientific in its upcoming release. The company is forecasted to report an EPS of $0.65, showcasing a 18.18% upward movement from the corresponding quarter of the prior year. Simultaneously, our latest consensus estimate expects the revenue to be $4.39 billion, showing a 17.85% escalation compared to the year-ago quarter.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $2.46 per share and revenue of $16.58 billion, indicating changes of +20% and +16.4%, respectively, compared to the previous year.
Investors should also note any recent changes to analyst estimates for Boston Scientific. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, there's been no change in the Zacks Consensus EPS estimate. As of now, Boston Scientific holds a Zacks Rank of #3 (Hold).
Investors should also note Boston Scientific's current valuation metrics, including its Forward P/E ratio of 36.77. Its industry sports an average Forward P/E of 24.61, so one might conclude that Boston Scientific is trading at a premium comparatively.
We can also see that BSX currently has a PEG ratio of 2.66. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Medical - Products industry had an average PEG ratio of 2.31 as trading concluded yesterday.
The Medical - Products industry is part of the Medical sector. This group has a Zacks Industry Rank of 85, putting it in the top 34% of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.